EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study

Charles Poiraud, Xavier Lenne, Amélie Bruandet, Didier Theis, Nicolas Bertrand, Anthony Turpin, Stephanie Truant, Mehdi El Amrani

World Journal of Surgical Oncology · 06.05.2024 · 22 (1)

DOI: 10.1186/s12957-024-03393-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgical Oncology, online erschienen am 06.05.2024. Verfasst von Charles Poiraud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatectomy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant chemotherapy (AC) improves the prognosis after pancreatic ductal adenocarcinoma (PDAC) resection. However, previous studies have shown that a large proportion of patients do not receive or complete AC. This national study examined the risk factors for the omission or interruption of AC.

Methods

Data of all patients who underwent pancreatic surgery for PDAC in France between January 2012 and December 2017 were extracted from the French National Administrative Database. We considered “omission of adjuvant chemotherapy” (OAC) all patients who failed to receive any course of gemcitabine within 12 postoperative weeks and “interruption of AC” (IAC) was defined as less than 18 courses of AC.

Results

A total of 11 599 patients were included in this study. Pancreaticoduodenectomy was the most common procedure (76.3%), and 31% of the patients experienced major postoperative complications. OACs and IACs affected 42% and 68% of the patients, respectively. Ultimately, only 18.6% of the cohort completed AC. Patients who underwent surgery in a high-volume centers were less affected by postoperative complications, with no impact on the likelihood of receiving AC. Multivariate analysis showed that age ≥ 80 years, Charlson comorbidity index (CCI) ≥ 4, and major complications were associated with OAC (OR = 2.19; CI 95% [1.79–2.68]; OR = 1.75; CI 95% [1.41–2.18] and OR = 2.37; CI 95% [2.15–2.62] respectively). Moreover, age ≥ 80 years and CCI 2–3 or ≥ 4 were also independent risk factors for IAC (OR = 1.54, CI 95% [1.1–2.15]; OR = 1.43, CI 95% [1.21–1.68]; OR = 1.47, CI 95% [1.02–2.12], respectively).

Conclusion

Sequence surgery followed by chemotherapy is associated with a high dropout rate, especially in octogenarian and comorbid patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalPancreatectomyHumansFemaleMaleAgedChemotherapy, AdjuvantFranceMiddle AgedAged, 80 and overPrognosisFollow-Up StudiesPancreaticoduodenectomyPostoperative ComplicationsSurvival RateRetrospective StudiesGemcitabineRisk FactorsDeoxycytidine

Stichwörter der Autor:innen

Adjuvant chemotherapyHospital volumePancreatic adenocarcinomaPancreatic cancer surgery

Substanzen

GemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France.
  • University of Lille, 59000, Lille, France.
  • Department of Medical Information, CHRU de Lille, 59000, Lille, France.
  • Medical Oncology Department, CHU de Lille, 59000, Lille, France.
  • Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France. mehdi_elamrani@hotmail.fr.
  • University of Lille, 59000, Lille, France. mehdi_elamrani@hotmail.fr.

Zitieren

APA

Poiraud, C., Lenne, X., Bruandet, A., Theis, D., Bertrand, N., Turpin, A., Truant, S., & El Amrani, M. (2024). Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World Journal of Surgical Oncology, 22(1). https://doi.org/10.1186/s12957-024-03393-7

Vancouver

Poiraud C, Lenne X, Bruandet A, Theis D, Bertrand N, Turpin A, et al. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World Journal of Surgical Oncology. 2024;22(1). doi:10.1186/s12957-024-03393-7

BibTeX
@article{Poiraud2024,
  author = {Poiraud, Charles and Lenne, Xavier and Bruandet, Amélie and Theis, Didier and Bertrand, Nicolas and Turpin, Anthony and Truant, Stephanie and El Amrani, Mehdi},
  title = {Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study},
  journal = {World Journal of Surgical Oncology},
  year = {2024},
  volume = {22},
  number = {1},
  doi = {10.1186/s12957-024-03393-7}
}
Kostenlos starten →